These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 29277758)
1. Sphingosine Induces Apoptosis and Down-regulation of Ahn EH; Lee MB; Seo DJ; Lee J; Kim Y; Gupta K Anticancer Res; 2018 Jan; 38(1):71-76. PubMed ID: 29277758 [TBL] [Abstract][Full Text] [Related]
2. Regulation of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma. Ahn EH Anticancer Res; 2013 May; 33(5):2029-35. PubMed ID: 23645752 [TBL] [Abstract][Full Text] [Related]
3. PAX3-FOXO1 is essential for tumour initiation and maintenance but not recurrence in a human myoblast model of rhabdomyosarcoma. Pandey PR; Chatterjee B; Olanich ME; Khan J; Miettinen MM; Hewitt SM; Barr FG J Pathol; 2017 Apr; 241(5):626-637. PubMed ID: 28138962 [TBL] [Abstract][Full Text] [Related]
4. Loss of MST/Hippo Signaling in a Genetically Engineered Mouse Model of Fusion-Positive Rhabdomyosarcoma Accelerates Tumorigenesis. Oristian KM; Crose LES; Kuprasertkul N; Bentley RC; Lin YT; Williams N; Kirsch DG; Linardic CM Cancer Res; 2018 Oct; 78(19):5513-5520. PubMed ID: 30093562 [TBL] [Abstract][Full Text] [Related]
5. Acquisition of an oncogenic fusion protein serves as an initial driving mutation by inducing aneuploidy and overriding proliferative defects. Loupe JM; Miller PJ; Bonner BP; Maggi EC; Vijayaraghavan J; Zabaleta J; Taylor CM; Tsien F; Crabtree JS; Hollenbach AD Oncotarget; 2016 Sep; 7(39):62814-62835. PubMed ID: 27588498 [TBL] [Abstract][Full Text] [Related]
6. Secreted Frizzled-Related Protein 3 (SFRP3) Is Required for Tumorigenesis of PAX3-FOXO1-Positive Alveolar Rhabdomyosarcoma. Kephart JJ; Tiller RG; Crose LE; Slemmons KK; Chen PH; Hinson AR; Bentley RC; Chi JT; Linardic CM Clin Cancer Res; 2015 Nov; 21(21):4868-80. PubMed ID: 26071485 [TBL] [Abstract][Full Text] [Related]
7. Targeting KDM4 for treating PAX3-FOXO1-driven alveolar rhabdomyosarcoma. Singh S; Abu-Zaid A; Jin H; Fang J; Wu Q; Wang T; Feng H; Quarni W; Shao Y; Maxham L; Abdolvahabi A; Yun MK; Vaithiyalingam S; Tan H; Bowling J; Honnell V; Young B; Guo Y; Bajpai R; Pruett-Miller SM; Grosveld GC; Hatley M; Xu B; Fan Y; Wu G; Chen EY; Chen T; Lewis PW; Rankovic Z; Li Y; Murphy AJ; Easton J; Peng J; Chen X; Wang R; White SW; Davidoff AM; Yang J Sci Transl Med; 2022 Jul; 14(653):eabq2096. PubMed ID: 35857643 [TBL] [Abstract][Full Text] [Related]
8. Aurora A Kinase Inhibition Destabilizes PAX3-FOXO1 and MYCN and Synergizes with Navitoclax to Induce Rhabdomyosarcoma Cell Death. Ommer J; Selfe JL; Wachtel M; O'Brien EM; Laubscher D; Roemmele M; Kasper S; Delattre O; Surdez D; Petts G; Kelsey A; Shipley J; Schäfer BW Cancer Res; 2020 Feb; 80(4):832-842. PubMed ID: 31888889 [TBL] [Abstract][Full Text] [Related]
10. Small molecule inhibition of PAX3-FOXO1 through AKT activation suppresses malignant phenotypes of alveolar rhabdomyosarcoma. Jothi M; Mal M; Keller C; Mal AK Mol Cancer Ther; 2013 Dec; 12(12):2663-74. PubMed ID: 24107448 [TBL] [Abstract][Full Text] [Related]
11. Interleukin-24 (IL24) Is Suppressed by PAX3-FOXO1 and Is a Novel Therapy for Rhabdomyosarcoma. Lacey A; Hedrick E; Cheng Y; Mohankumar K; Warren M; Safe S Mol Cancer Ther; 2018 Dec; 17(12):2756-2766. PubMed ID: 30190424 [TBL] [Abstract][Full Text] [Related]
12. Reduced B7-H3 expression by PAX3-FOXO1 knockdown inhibits cellular motility and promotes myogenic differentiation in alveolar rhabdomyosarcoma. Kanayama T; Miyachi M; Sugimoto Y; Yagyu S; Kikuchi K; Tsuchiya K; Iehara T; Hosoi H Sci Rep; 2021 Sep; 11(1):18802. PubMed ID: 34552155 [TBL] [Abstract][Full Text] [Related]
13. Identification of PAX3-FKHR-regulated genes differentially expressed between alveolar and embryonal rhabdomyosarcoma: focus on MYCN as a biologically relevant target. Mercado GE; Xia SJ; Zhang C; Ahn EH; Gustafson DM; Laé M; Ladanyi M; Barr FG Genes Chromosomes Cancer; 2008 Jun; 47(6):510-20. PubMed ID: 18335505 [TBL] [Abstract][Full Text] [Related]
14. Fusion transcriptome profiling provides insights into alveolar rhabdomyosarcoma. Xie Z; Babiceanu M; Kumar S; Jia Y; Qin F; Barr FG; Li H Proc Natl Acad Sci U S A; 2016 Nov; 113(46):13126-13131. PubMed ID: 27799565 [TBL] [Abstract][Full Text] [Related]
18. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma. Taulli R; Scuoppo C; Bersani F; Accornero P; Forni PE; Miretti S; Grinza A; Allegra P; Schmitt-Ney M; Crepaldi T; Ponzetto C Cancer Res; 2006 May; 66(9):4742-9. PubMed ID: 16651427 [TBL] [Abstract][Full Text] [Related]
19. Expression and activity of vascular endothelial growth factor and metalloproteinases in alveolar and embryonal rhabdomyosarcoma cell lines. Onisto M; Slongo ML; Gregnanin L; Gastaldi T; Carli M; Rosolen A Int J Oncol; 2005 Sep; 27(3):791-8. PubMed ID: 16077930 [TBL] [Abstract][Full Text] [Related]